Study of the Role of Soluble Inhibitor of Interleukin 22, Interleukin 22 Binding Protein (IL-22BP), in Chronic Inflammatory Bowel Disease (IL-22BP MICI)

Nantes University Hospital (NUH)

Status: Terminated

Conditions: Inflammatory Bowel Disease

Treatments: Other: Non interventional study

Study type: Observational

Funder types: Other

Identifiers

NCT02847052

RC14_0042

Details and patient eligibility

About

IL-22 is an IL-10 family cytokine that plays major actions to increase intestinal epithelial barrier function and regeneration during experimental colitis. IL-22 binding protein is a small, soluble, and secreted protein potently inhibiting IL-22 actions through preventing the binding with IL-22 Recepteur. This study aims at characterizing how IL-22 binding protein is regulated in Inflammatory bowel disease to better understand the way IL-22 acts on epithelial cells during flares of the disease.

Enrollment: 52 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion criteria

1. Crohn's disease or Ulcerative colitis
2. Healthy controls paired for age and sex
3. Samples availability in the biobank
4. Signed consent
5. No (Immune Mediated Inflammatory Disorders other than Inflammatory bowel disease
6. No other conditions predicted or known to affect IL-22/IL-22 recepteur /IL-22 binding protein regulation
7. Availability of clinical data
8. Age >18 y.o.
9. No pregnancy